FR2902427B1 - Derives de phenylpentadienoyle - Google Patents

Derives de phenylpentadienoyle

Info

Publication number
FR2902427B1
FR2902427B1 FR0605418A FR0605418A FR2902427B1 FR 2902427 B1 FR2902427 B1 FR 2902427B1 FR 0605418 A FR0605418 A FR 0605418A FR 0605418 A FR0605418 A FR 0605418A FR 2902427 B1 FR2902427 B1 FR 2902427B1
Authority
FR
France
Prior art keywords
phenylpentadienoyle
derivatives
phenylpentadienoyle derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0605418A
Other languages
English (en)
Other versions
FR2902427A1 (fr
Inventor
Michel Perez
Marie Lamothe
Grand Bruno Le
Robert Letienne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0605418A priority Critical patent/FR2902427B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to CA002655728A priority patent/CA2655728A1/fr
Priority to AT07765492T priority patent/ATE500223T1/de
Priority to ARP070102684A priority patent/AR061519A1/es
Priority to DE602007012888T priority patent/DE602007012888D1/de
Priority to CN2007800223489A priority patent/CN101472894B/zh
Priority to EP07765492A priority patent/EP2046748B1/fr
Priority to BRPI0713582-3A priority patent/BRPI0713582A2/pt
Priority to JP2009515858A priority patent/JP5268897B2/ja
Priority to RU2008149917/04A priority patent/RU2440985C2/ru
Priority to UAA200900375A priority patent/UA97370C2/ru
Priority to US12/305,447 priority patent/US8022064B2/en
Priority to AU2007263049A priority patent/AU2007263049B2/en
Priority to PCT/EP2007/056078 priority patent/WO2007147822A1/fr
Priority to ES07765492T priority patent/ES2361061T3/es
Priority to KR1020097000945A priority patent/KR20090031735A/ko
Priority to MX2008016446A priority patent/MX2008016446A/es
Priority to NZ573591A priority patent/NZ573591A/en
Priority to TW096122075A priority patent/TW200815371A/zh
Publication of FR2902427A1 publication Critical patent/FR2902427A1/fr
Publication of FR2902427B1 publication Critical patent/FR2902427B1/fr
Application granted granted Critical
Priority to IL195869A priority patent/IL195869A0/en
Priority to TNP2008000521A priority patent/TNSN08521A1/en
Priority to ZA2008/10629A priority patent/ZA200810629B/en
Priority to MA31483A priority patent/MA31131B1/fr
Priority to NO20090269A priority patent/NO20090269L/no
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
FR0605418A 2006-06-19 2006-06-19 Derives de phenylpentadienoyle Expired - Fee Related FR2902427B1 (fr)

Priority Applications (24)

Application Number Priority Date Filing Date Title
FR0605418A FR2902427B1 (fr) 2006-06-19 2006-06-19 Derives de phenylpentadienoyle
ES07765492T ES2361061T3 (es) 2006-06-19 2007-06-19 Derivados de fenilpentadienoílo y su utilización como antagonistas de par-1.
ARP070102684A AR061519A1 (es) 2006-06-19 2007-06-19 Derivados de fenilpentadienoilo y composicion farmaceutica
DE602007012888T DE602007012888D1 (de) 2006-06-19 2007-06-19 Phenylpentadienoylderivate und ihre verwendung als par-1-antagonisten
CN2007800223489A CN101472894B (zh) 2006-06-19 2007-06-19 苯基戊二烯衍生物及其作为par1拮抗剂的用途
EP07765492A EP2046748B1 (fr) 2006-06-19 2007-06-19 Dérivés de phénylpentadienoyl et utilisation comme antagonistes de par 1
BRPI0713582-3A BRPI0713582A2 (pt) 2006-06-19 2007-06-19 derivados de fenilpentadienoìla e seu uso como antagonistas de par um
JP2009515858A JP5268897B2 (ja) 2006-06-19 2007-06-19 フェニルペンタジエノイル誘導体およびｐａｒ１拮抗薬としてのそれらの使用
RU2008149917/04A RU2440985C2 (ru) 2006-06-19 2007-06-19 Производные фенилпентадиеноила и их применение в качестве антагонистов par 1
AT07765492T ATE500223T1 (de) 2006-06-19 2007-06-19 Phenylpentadienoylderivate und ihre verwendung als par-1-antagonisten
US12/305,447 US8022064B2 (en) 2006-06-19 2007-06-19 Phenylpentadienoyl derivatives and their use as PAR 1 antagonists
AU2007263049A AU2007263049B2 (en) 2006-06-19 2007-06-19 Phenylpentadienoyl derivatives and their use as par 1 antagonists
CA002655728A CA2655728A1 (fr) 2006-06-19 2007-06-19 Derives de phenylpentadienoyl et utilisation comme antagonistes de par 1
PCT/EP2007/056078 WO2007147822A1 (fr) 2006-06-19 2007-06-19 Dérivés de phénylpentadienoyl et utilisation comme antagonistes de par 1
UAA200900375A UA97370C2 (ru) 2006-06-19 2007-06-19 Производные фенилпентадиеноила и их применение в качестве антагонистов par 1
MX2008016446A MX2008016446A (es) 2006-06-19 2007-06-19 Derivados de fenilpentadienoilo y su uso como antagonistas de receptor activado por proteasa 1.
NZ573591A NZ573591A (en) 2006-06-19 2007-06-19 Phenylpentadienoyl derivatives and their use as par 1 antagonists
KR1020097000945A KR20090031735A (ko) 2006-06-19 2007-06-19 페닐펜타디엔노일 유도체 및 ｐａｒ 1 길항제로서의 용도
TW096122075A TW200815371A (en) 2006-06-19 2007-06-20 Phenylpentadienoyl derivatives
IL195869A IL195869A0 (en) 2006-06-19 2008-12-11 Phenylpentadienoyl derivatives and their use as par 1 antagonists
TNP2008000521A TNSN08521A1 (en) 2006-06-19 2008-12-16 Phenylpentadienoyl derivatives and their use as par 1 antagonists
ZA2008/10629A ZA200810629B (en) 2006-06-19 2008-12-17 Phenylpentadienoyl derivatives and their use as par 1 antagonists
MA31483A MA31131B1 (fr) 2006-06-19 2008-12-18 Derives de phenylpentadienoyl et utilisation comme antagonistes de par1
NO20090269A NO20090269L (no) 2006-06-19 2009-01-16 Fenolpentadienoylderivater og deres anvendelse som PAR-1-antagonister

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0605418A FR2902427B1 (fr) 2006-06-19 2006-06-19 Derives de phenylpentadienoyle

Publications (2)

Publication Number Publication Date
FR2902427A1 FR2902427A1 (fr) 2007-12-21
FR2902427B1 true FR2902427B1 (fr) 2008-08-22

Family

ID=37622010

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0605418A Expired - Fee Related FR2902427B1 (fr) 2006-06-19 2006-06-19 Derives de phenylpentadienoyle

Country Status (24)

Country Link
US (1) US8022064B2 (fr)
EP (1) EP2046748B1 (fr)
JP (1) JP5268897B2 (fr)
KR (1) KR20090031735A (fr)
CN (1) CN101472894B (fr)
AR (1) AR061519A1 (fr)
AT (1) ATE500223T1 (fr)
AU (1) AU2007263049B2 (fr)
BR (1) BRPI0713582A2 (fr)
CA (1) CA2655728A1 (fr)
DE (1) DE602007012888D1 (fr)
ES (1) ES2361061T3 (fr)
FR (1) FR2902427B1 (fr)
IL (1) IL195869A0 (fr)
MA (1) MA31131B1 (fr)
MX (1) MX2008016446A (fr)
NO (1) NO20090269L (fr)
NZ (1) NZ573591A (fr)
RU (1) RU2440985C2 (fr)
TN (1) TNSN08521A1 (fr)
TW (1) TW200815371A (fr)
UA (1) UA97370C2 (fr)
WO (1) WO2007147822A1 (fr)
ZA (1) ZA200810629B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104496879A (zh) * 2015-01-13 2015-04-08 佛山市赛维斯医药科技有限公司 一种含腈基苯和二烯氟代金刚烷结构的化合物和用途
WO2019190177A1 (fr) * 2018-03-27 2019-10-03 주식회사 바이오웨이 Dérivé de (2e,4e)-5-phényl-penta-2,4-dièn-1-one

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61106564A (ja) * 1984-10-30 1986-05-24 Terumo Corp 不飽和脂肪酸アミド誘導体およびこれを含有する血小板凝集抑制剤
JPS61137866A (ja) * 1984-12-07 1986-06-25 Terumo Corp イミダゾ−ル誘導体およびこれを含有する血小板凝集抑制剤
US4792553A (en) * 1986-02-04 1988-12-20 Terumo Kabushiki Kaisha Diene derivatives and vasodilators containing the same
FR2917622B1 (fr) * 2007-06-19 2009-10-23 Pierre Fabre Medicament Sa Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale.

Also Published As

Publication number Publication date
US8022064B2 (en) 2011-09-20
BRPI0713582A2 (pt) 2012-10-23
MX2008016446A (es) 2009-01-22
AU2007263049B2 (en) 2011-10-27
RU2440985C2 (ru) 2012-01-27
IL195869A0 (en) 2009-09-01
ES2361061T3 (es) 2011-06-13
CA2655728A1 (fr) 2007-12-27
RU2008149917A (ru) 2010-07-27
JP5268897B2 (ja) 2013-08-21
EP2046748B1 (fr) 2011-03-02
UA97370C2 (ru) 2012-02-10
ZA200810629B (en) 2010-02-24
JP2009541258A (ja) 2009-11-26
CN101472894A (zh) 2009-07-01
MA31131B1 (fr) 2010-02-01
DE602007012888D1 (de) 2011-04-14
US20100003260A1 (en) 2010-01-07
AU2007263049A1 (en) 2007-12-27
KR20090031735A (ko) 2009-03-27
TNSN08521A1 (en) 2010-04-14
CN101472894B (zh) 2012-09-05
NZ573591A (en) 2010-10-29
TW200815371A (en) 2008-04-01
NO20090269L (no) 2009-02-27
ATE500223T1 (de) 2011-03-15
FR2902427A1 (fr) 2007-12-21
EP2046748A1 (fr) 2009-04-15
WO2007147822A1 (fr) 2007-12-27
AR061519A1 (es) 2008-09-03

Similar Documents

Publication Publication Date Title
FR20C1038I2 (fr) Derives de benzamidazole
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
DK2035394T3 (da) 2-pyrazincarboxamidderivater
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0817935A2 (pt) Derivados de biarila
BRPI0812155A2 (pt) derivados de espiroindolinona
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
CR10841A (es) Imidazotriazinas imidazopirimidinas inhibidores de cinasa
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI0813836A2 (pt) Derivados pirazólicos
FR2902426B1 (fr) Derives de cinnamoyl-piperazine
BRPI0720220A2 (pt) Derivados de quinolinas antibacterianos
DK2152370T3 (da) Aryletherpyridazinonderivater
ATE544764T1 (de) 5-hydroxymethyloxazolidin-2-onderivate
BRPI0817579A2 (pt) Derivados de tiazol
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
BRPI0814718A2 (pt) Derivados de isoxazol-imidazol

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20130228